Continuous Glucose Monitoring Alarms in Adults with Type 1 Diabetes: User Characteristics and the Impact of Hypoglycemia and Hyperglycemia Alarm Thresholds on Glycemic Control
Diabetes Technology & Therapeutics · 2024
DOI: 10.1089/dia.2023.0460 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes Technology & Therapeutics, 2024. Verfasst von Tomás González-Vidal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Nutrition, Hospital Universitario Central de Asturias/University of Oviedo, Oviedo, Spain. Hauptthemen laut MEDLINE: Clinical Alarms, Diabetes Mellitus, Type 1, Glycemic Control, Hyperglycemia. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Few studies have evaluated the implications of the alarm thresholds of continuous glucose monitoring (CGM) systems for individuals with diabetes. The present study aimed to investigate the influence of hypoglycemia and hyperglycemia alarm thresholds on glycemic control in adults with type 1 diabetes (T1DM) and the characteristics of patients who use these alarms more frequently.
Methods
This observational cross-sectional study included 873 users of the FreeStyle Libre 2 system (501 men, median age 48 years, range 18–90 years) with T1DM from a single center. We investigated the role of demographic and metabolic factors on the use of alarms and the impact of hypoglycemia and hyperglycemia alarms and their thresholds on glycemic control.
Results
Alarm users were older than nonusers (median age 49 vs. 43 years, respectively; P < 0.001). The hypoglycemia alarms were set by 76.1% of women and by 69.1% of men ( P = 0.022). The hypoglycemia alarms reduced hypoglycemia features and glucose variability, although at the expense of shorter time in range. The higher the hypoglycemia alarm threshold, the greater these effects. The hyperglycemia alarms were effective in reducing hyperglycemia and lowering the glucose management indicator, although at the expense of a greater tendency to hypoglycemia. The lower the hyperglycemia alarm threshold, the greater these effects.
Conclusions
CGM alarms contribute to better glycemic control. However, hypoglycemia and hyperglycemia alarms have advantages and disadvantages. Adults with T1DM should explore, under medical supervision, which alarm thresholds will best help them achieve their individual glycemic goals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Nutrition, Hospital Universitario Central de Asturias/University of Oviedo, Oviedo, Spain.
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.
- Department of Medicine, University of Oviedo, Oviedo, Spain.
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Zitieren
APA
González-Vidal, T., Rivas-Otero, D., Agüeria-Cabal, P., Ramos-Ruiz, G., Delgado, E., & Menéndez-Torre, E. (2024). Continuous Glucose Monitoring Alarms in Adults with Type 1 Diabetes: User Characteristics and the Impact of Hypoglycemia and Hyperglycemia Alarm Thresholds on Glycemic Control. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2023.0460
Vancouver
González-Vidal T, Rivas-Otero D, Agüeria-Cabal P, Ramos-Ruiz G, Delgado E, Menéndez-Torre E. Continuous Glucose Monitoring Alarms in Adults with Type 1 Diabetes: User Characteristics and the Impact of Hypoglycemia and Hyperglycemia Alarm Thresholds on Glycemic Control. Diabetes Technology & Therapeutics. 2024. doi:10.1089/dia.2023.0460
BibTeX
@article{GonzlezVidal2024,
author = {González-Vidal, Tomás and Rivas-Otero, Diego and Agüeria-Cabal, Pablo and Ramos-Ruiz, Guillermo and Delgado, Elías and Menéndez-Torre, Edelmiro},
title = {Continuous Glucose Monitoring Alarms in Adults with Type 1 Diabetes: User Characteristics and the Impact of Hypoglycemia and Hyperglycemia Alarm Thresholds on Glycemic Control},
journal = {Diabetes Technology & Therapeutics},
year = {2024},
doi = {10.1089/dia.2023.0460}
}
EUVIMED